New hope for babies with rare seizure disorder: drug trial targets SCN2A gene

NCT ID NCT07019922

Recruiting now Disease control Sponsor: Praxis Precision Medicines Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Aug 04, 2026 · Updated 2 times

Summary

This study tests a medicine called elsunersen in 40 children with a rare, severe form of epilepsy caused by changes in the SCN2A gene. The goal is to see if the drug can safely reduce how often seizures happen over 24 weeks. Children must have started having seizures before 3 months old and have at least 4 seizures per month to join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPILEPTIC ENCEPHALOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental and epileptic encephalopathy developmental and epileptic encephalopathy, 11 epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EPILEPTIC ENCEPHALOPATHY SCN2A ENCEPHALOPATHY

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Praxis Research Site
RECRUITING

San Diego, California, 92123, United States
Praxis Research Site
RECRUITING

Aurora, Colorado, 80045, United States
Praxis Research Site
RECRUITING

Chicago, Illinois, 60612, United States
Praxis Research Site
RECRUITING

Cincinnati, Ohio, 45229, United States
Praxis Research Site
RECRUITING

Philadelphia, Pennsylvania, 19104, United States
Praxis Research Site
RECRUITING

Memphis, Tennessee, 38105, United States
Praxis Research Site
WITHDRAWN

Porto Alegre, 90035, Brazil
Praxis Research Site
WITHDRAWN

São Paulo, 05403, Brazil
Praxis Research Site
RECRUITING

Bonn, Bonn, 53127, Germany
Praxis Research Site
RECRUITING

Rome, 00165, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.